First Preclinical Development Candidate for Nucleome Therapeutics - Poll - MDSpire

First Preclinical Development Candidate for Nucleome Therapeutics

First-in-class monoclonal antibody agonist program for inflammation

  • January 19, 2026

  • 2 min

Share

Original Source(s)

First Preclinical Development Candidate for Nucleome Therapeutics

  • January 19, 2026

Related Content

Attaining sustainability in inflammatory bowel disease

ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries

Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis